Phase 3 Epilepsy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 2 to 55 years old at the time of screening
• People (or their parent or legal guardian) who are willing and able to give written consent to participate
• People who have been diagnosed with Lennox-Gastaut Syndrome (LGS), which includes all of the following: evidence of at least one type of major, countable motor seizure; a brain wave test (EEG) showing results consistent with LGS; abnormal cognitive (thinking and learning) development; and seizures that began at age 11 or younger

Who may not be able to join:

• People who are known to be sensitive or allergic to, or have previously been given, the drug clemizole HCl
• People with a known history of long QT syndrome (a heart rhythm condition) or any significant heart tracing (ECG) abnormality, such as a recent heart attack or a serious irregular heartbeat
• People who have a family history of sudden cardiac death, unexplained death, or death caused by a heart rhythm problem that may be linked to a condition called QT prolongation
• People whose seizures are caused by illicit drug or alcohol use, infection, a brain tumour, nerve damage, a degenerative brain condition, a metabolic illness, a lack of oxygen to the brain within the past 6 months that required resuscitation, or any other condition that, in the trial doctor's opinion, could affect seizure control
• People who have had epilepsy surgery within the 6 months before screening, or who have epilepsy surgery planned during the study
• People who are currently taking the drug fenfluramine at the same time
• People who have previously taken or are currently taking the drug lorcaserin

Important: Always verify eligibility with the trial site directly before applying.